ravulizumab NMOSD
Selected indexed studies
- Ravulizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder. (Ann Neurol, 2023) [PMID:36866852]
- Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management. (J Neurol, 2024) [PMID:37676297]
- Network Meta-analysis of Ravulizumab and Alternative Interventions for the Treatment of Neuromyelitis Optica Spectrum Disorder. (Neurol Ther, 2024) [PMID:38722571]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Ravulizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder. (2023) pubmed
- Network Meta-analysis of Ravulizumab and Alternative Interventions for the Treatment of Neuromyelitis Optica Spectrum Disorder. (2024) pubmed
- Ravulizumab and other complement inhibitors for the treatment of autoimmune disorders. (2025) pubmed
- Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management. (2024) pubmed
- Post marketing real-world experience of ravulizumab in NMOSD. (2025) pubmed
- PMID:38917264 (2024) pubmed
- An evaluation of ravulizumab for the treatment of neuromyelitis optica spectrum disorder. (2024) pubmed
- Ravulizumab-related meningococcal sepsis post rituximab. (2025) pubmed
- Safety and efficacy of ravulizumab in patients with NMOSD previously treated with rituximab: A post hoc analysis of the CHAMPION-NMOSD trial. (2026) pubmed
- Immunotherapies in neuromyelitis optica: Bayesian network meta-analysis. (2025) pubmed